TY  - GEN
AU  - Zahonero, Cristina
AU  - Aguilera, Pilar
AU  - Ramírez-Castillejo, Carmen
AU  - Pajares, Marta
AU  - Bolos, Victoria
AU  - Cantero, Diana
AU  - Pérez-Núñez, Ángel
AU  - Hernández-Laín, Aurelio
AU  - Sánchez-Gómez, Pilar
AU  - Sepúlveda, Juan Manuel
PY  - 2015
DO  - 10.1158/1535-7163.MCT-14-0736
UR  - http://hdl.handle.net/20.500.12105/10786
AB  - Glioblastomas (GBM) are devastating tumors in which there has been little clinical improvement in the last decades. New molecularly directed therapies are under development. EGFR is one of the most promising targets, as this receptor is mutated and/or...
LA  - eng
PB  - American Association for Cancer Research (AACR)
KW  - Xenograft Model Antitumor Assays
KW  - Animals
KW  - Blotting, Western
KW  - Cell Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Screening Assays, Antitumor
KW  - ErbB Receptors
KW  - Gene Amplification
KW  - Glioblastoma
KW  - Humans
KW  - Mice, Nude
KW  - Phosphorylation
KW  - Quinazolinones
KW  - Reverse Transcriptase Polymerase Chain Reaction
KW  - Signal Transduction
KW  - Survival Analysis
KW  - Time Factors
KW  - Tumor Burden
KW  - Tumor Cells, Cultured
TI  - Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.
TY  - research article
ER  -